Drug Price Trends for NDC 42806-0081

Average Pharmacy Cost for 42806-0081

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 42806-0081

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 42806-0081

Last updated: February 23, 2026

What is NDC 42806-0081?

NDC 42806-0081 corresponds to Lupron Depot (leuprolide acetate for depot suspension). It is an injectable gonadotropin-releasing hormone (GnRH) agonist used primarily for prostate cancer, endometriosis, and central precocious puberty.

Market Overview

Treatment Indications and Market Size

• Prostate Cancer: The primary indication, with a prevalence of approximately 1.3 million diagnosed cases in the United States as of 2022 (American Cancer Society).

• Endometriosis: Affects around 10% of reproductive-aged women, roughly 6.5 million in the U.S. (Centers for Disease Control and Prevention).

• Central Precocious Puberty: Rare, but significant within pediatric endocrinology.

Competitive Landscape

• Major brands include Lupron Depot (original drug by Takeda) and generic formulations marketed by multiple manufacturers.

• Generic competition has increased since patent expiry in the early 2010s; this impacts price stability and market share.

Patent and Regulatory Status

• The original patent for Lupron Depot lapsed in 2013 for many indications, leading to an increase in generic options.

• FDA-approved generics have entered the market, leading to decreased prices and increased consumption.

Key Market Drivers

• Increasing diagnosis rates, especially for prostate cancer due to aging population.

• Continued use in endometriosis management and central precocious puberty.

• Expansion into new indications, such as breast cancer and other hormone-sensitive conditions.

Market Trends

• The injectable form remains dominant, with an annual revenue estimate of approximately $400 million in the U.S. (EvaluatePharma, 2022).

• The rise of biosimilar and generic options has driven price competition.

Price Projections

Current Pricing

• Brand-name Lupron Depot (e.g., 7.5 mg IM injection): Retail prices range from $2,200 to $2,700 per dose.

• Generic equivalents: Prices range approximately from $1,500 to $2,000 per dose, depending on supplier and formulation.

Future Price Trends (2023–2028)

Year	Price Range (per 7.5 mg dose)	Drivers
2023	$1,300 – $2,200	Increased generic competition, patent expiries in prior years.
2024	$1,200 – $2,000	Continued price erosion, payer pressure.
2025	$1,100 – $1,900	Market saturation, potential biosimilar entries.
2026	$1,000 – $1,800	Expansion of biosimilar options, loss of exclusivity for some formulations.
2027–2028	$900 – $1,700	Further commoditization, reduced margins.

Price Influencing Factors

• Market penetration of generics reduces prices annually by approximately 10–15%.

• Payer negotiations and formulary placements can skew prices toward lower-end estimates.

• Manufacturing costs decrease slightly due to scale and process efficiencies for biosimilars.

• Regulatory policies encouraging biosimilar uptake can accelerate price declines.

Competitive Price Benchmarks

Product Type	Approximate Price Range (per dose)	Notes
Original Lupron Depot	$2,200 – $2,700	Historically highest, now declining due to generics.
Generic Leuprolide Depot	$1,500 – $2,000	Competitive with biosimilar options.
Biosimilar Leuprolide	Projected $900 – $1,200	Entry expected around 2025–2026.

Market Entry and Pricing Strategies

• New Biosimilar Launch: Expected to enter at 10–20% discount relative to generics, establishing a new price floor over 12–24 months post-launch.

• Market Share Shifts: Biosimilars may capture 50–70% of the market within three years of launch, exerting downward pressure on all prices.

Key Takeaways

• NDC 42806-0081 (Lupron Depot) faces ongoing price declines due to patent expirations and market saturation with generics.

• Future prices are projected to fall between $900 and $1,700 per dose by 2028, driven primarily by biosimilar entry and payer dynamics.

• The market maintains a total annual revenue estimate of approximately $400 million in the U.S., with a significant portion influenced by generic and biosimilar competition.

• Manufacturers contemplating new formulations or biosimilars should anticipate aggressive price competition post-approval.

FAQs

1. When did patent expiration for Lupron Depot occur?
   Primary patents expired in 2013, facilitating generic entry.

2. What factors influence biosimilar adoption for leuprolide?
   Regulatory approval speed, payer policies, and clinician acceptance.

3. Are there regional price differences?
   Yes, U.S. prices tend to be higher than Europe or Asia due to market dynamics and negotiating power.

4. How do biosimilars impact brand-name pricing?
   They typically reduce prices by 10–30% initially and accelerate market share shifts.

5. What are regulatory hurdles in launching biosimilars for Lupron Depot?
   Demonstrating biosimilarity through comprehensive clinical and manufacturing data, plus gaining FDA approval documentation.

---

References

[1] American Cancer Society. (2022). Cancer facts & figures 2022.
[2] Centers for Disease Control and Prevention. (2022). Endometriosis prevalence statistics.
[3] EvaluatePharma. (2022). Oncology market intelligence report.
[4] FDA. (2022). Biosimilar Drug Development Guidance.